[{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"b72b0a64-54a8-4a42-8b82-b948a538ae47","acronym":"CAPRI","url":"https://clinicaltrials.gov/study/NCT03462342","created_at":"2021-01-18T17:04:00.829Z","updated_at":"2025-02-25T14:58:45.950Z","phase":"Phase 2","brief_title":"Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03462342 - CAPRI","lead_sponsor":"University of Pennsylvania","biomarkers":" HRD • BRCA • MUC16","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-31"},{"id":"a170957e-b723-496d-b981-b2bbe36c4fc4","acronym":"EFFORT","url":"https://clinicaltrials.gov/study/NCT03579316","created_at":"2021-01-18T17:36:17.068Z","updated_at":"2025-02-25T17:29:43.272Z","phase":"Phase 2","brief_title":"Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03579316 - EFFORT","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/07/2018","start_date":" 12/07/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-30"},{"id":"9b1c2dc1-3b24-43f9-b184-70bf85aad83b","acronym":"NCI-2018-01648","url":"https://clinicaltrials.gov/study/NCT03682289","created_at":"2021-01-18T18:03:10.694Z","updated_at":"2025-02-25T15:07:56.671Z","phase":"Phase 2","brief_title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","source_id_and_acronym":"NCT03682289 - NCI-2018-01648","lead_sponsor":"Rahul Aggarwal","biomarkers":" MSI • ATM • ARID1A • UGT1A1","pipe":" | ","alterations":" ATM mutation","tags":["MSI • ATM • ARID1A • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-01-28"},{"id":"1d507459-75e0-40d5-8168-57a298632833","acronym":"","url":"https://clinicaltrials.gov/study/NCT06732401","created_at":"2025-02-26T09:56:27.901Z","updated_at":"2025-02-26T09:56:27.901Z","phase":"Phase 3","brief_title":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06732401","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 630","initiation":"Initiation: 03/14/2025","start_date":" 03/14/2025","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-12-13"},{"id":"ae9e478e-e6fe-4a4a-997a-f85a6be1d091","acronym":"","url":"https://clinicaltrials.gov/study/NCT03801369","created_at":"2021-01-18T18:47:29.710Z","updated_at":"2025-02-25T15:08:15.103Z","phase":"Phase 2","brief_title":"Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03801369","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2 • ER • PGR • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["HER-2 • ER • PGR • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • Truqap (capivasertib) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-08-13"},{"id":"57e9cf07-fbd3-4b60-b000-b857b664ab20","acronym":"ATARI","url":"https://clinicaltrials.gov/study/NCT04065269","created_at":"2021-01-18T19:55:05.811Z","updated_at":"2025-02-25T15:08:44.072Z","phase":"Phase 2","brief_title":"ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss","source_id_and_acronym":"NCT04065269 - ATARI","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-07-11"},{"id":"122e5ddf-e06a-4539-a4fb-c6730d4e0338","acronym":"LATIFY","url":"https://clinicaltrials.gov/study/NCT05450692","created_at":"2022-07-11T12:56:21.525Z","updated_at":"2024-07-02T16:35:00.482Z","phase":"Phase 3","brief_title":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","source_id_and_acronym":"NCT05450692 - LATIFY","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 563","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 05/12/2025","primary_completion_date":" 05/12/2025","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2024-05-29"},{"id":"62aca2f8-43be-49bc-a240-562947c24958","acronym":"D5330C00004","url":"https://clinicaltrials.gov/study/NCT02264678","created_at":"2021-01-17T17:33:57.498Z","updated_at":"2024-07-02T16:35:02.492Z","phase":"Phase 1/2","brief_title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","source_id_and_acronym":"NCT02264678 - D5330C00004","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ATM • HRD • BRCA • RAD51C • RAD51D","pipe":" | ","alterations":" HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation • RAD51 mutation","tags":["HER-2 • ATM • HRD • BRCA • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • ceralasertib (AZD6738) • saruparib (AZD5305)"],"overall_status":"Recruiting","enrollment":" Enrollment 466","initiation":"Initiation: 10/31/2014","start_date":" 10/31/2014","primary_txt":" Primary completion: 08/05/2026","primary_completion_date":" 08/05/2026","study_txt":" Completion: 08/05/2026","study_completion_date":" 08/05/2026","last_update_posted":"2024-05-21"},{"id":"124724a9-c433-4ebd-b30a-756fba93c068","acronym":"LOTOS","url":"https://clinicaltrials.gov/study/NCT05941897","created_at":"2023-07-12T16:10:18.523Z","updated_at":"2024-07-02T16:35:02.636Z","phase":"Phase 2","brief_title":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","source_id_and_acronym":"NCT05941897 - LOTOS","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/21/2023","start_date":" 06/21/2023","primary_txt":" Primary completion: 07/29/2024","primary_completion_date":" 07/29/2024","study_txt":" Completion: 07/29/2025","study_completion_date":" 07/29/2025","last_update_posted":"2024-05-20"},{"id":"8a546e53-8398-4bf1-9589-03660de842b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03878095","created_at":"2021-01-18T19:07:08.982Z","updated_at":"2024-07-02T16:35:02.694Z","phase":"Phase 2","brief_title":"Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors","source_id_and_acronym":"NCT03878095","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Suspended","enrollment":" Enrollment 50","initiation":"Initiation: 01/30/2020","start_date":" 01/30/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-17"},{"id":"b3ec16de-b06c-4b4e-97bd-502739a6230d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02664935","created_at":"2021-01-18T12:59:26.753Z","updated_at":"2025-02-25T14:36:10.262Z","phase":"Phase 2","brief_title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02664935","lead_sponsor":"University of Birmingham","biomarkers":" NKX2-1 • TP63","pipe":"","alterations":" ","tags":["NKX2-1 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tagrisso (osimertinib) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Koselugo (selumetinib) • Truqap (capivasertib) • fexagratinib (ABSK091) • ceralasertib (AZD6738) • sitravatinib (MGCD516) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-13"},{"id":"059c44d0-f5a3-4e0a-b39e-6b8103e251ad","acronym":"PIONeeR","url":"https://clinicaltrials.gov/study/NCT03833440","created_at":"2021-01-18T18:55:39.473Z","updated_at":"2024-07-02T16:35:06.100Z","phase":"Phase 2","brief_title":"Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance","source_id_and_acronym":"NCT03833440 - PIONeeR","lead_sponsor":"Assistance Publique Hopitaux De Marseille","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • Orpathys (savolitinib) • ceralasertib (AZD6738) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 10/08/2019","start_date":" 10/08/2019","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-03"},{"id":"f6c20e60-2c54-4ca4-a32a-1818b76a2ae4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03770429","created_at":"2021-01-18T18:39:17.898Z","updated_at":"2025-02-25T15:08:09.884Z","phase":"Phase 1","brief_title":"AZD6738 for Patients With Progressive MDS or CMML","source_id_and_acronym":"NCT03770429","lead_sponsor":"Massachusetts General Hospital","biomarkers":" SF3B1 • SRSF2 • U2AF1 • ZRSR2","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1 • SRSF2 • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 08/05/2019","start_date":" 08/05/2019","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-03-15"},{"id":"91cb7612-511e-486c-a165-6d57df8ff07f","acronym":"VIOLETTE","url":"https://clinicaltrials.gov/study/NCT03330847","created_at":"2021-01-17T17:33:58.725Z","updated_at":"2024-07-02T16:35:16.588Z","phase":"Phase 2","brief_title":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","source_id_and_acronym":"NCT03330847 - VIOLETTE","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • HRD","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 273","initiation":"Initiation: 03/07/2018","start_date":" 03/07/2018","primary_txt":" Primary completion: 11/13/2020","primary_completion_date":" 11/13/2020","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-03-04"},{"id":"86171696-4f6d-47df-9ec6-eddd532805f3","acronym":"NCI-2019-04148","url":"https://clinicaltrials.gov/study/NCT04090567","created_at":"2021-01-18T20:01:10.424Z","updated_at":"2024-07-02T16:35:22.234Z","phase":"Phase 2","brief_title":"Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","source_id_and_acronym":"NCT04090567 - NCI-2019-04148","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • BRCA","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738) • Recentin (cediranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-01-25"},{"id":"c9bba479-5e84-46c9-bf12-d98b22cedf99","acronym":"MONETTE","url":"https://clinicaltrials.gov/study/NCT05061134","created_at":"2021-09-29T11:53:52.299Z","updated_at":"2024-07-02T16:35:22.916Z","phase":"Phase 2","brief_title":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition","source_id_and_acronym":"NCT05061134 - MONETTE","lead_sponsor":"AstraZeneca","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 194","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 04/12/2024","primary_completion_date":" 04/12/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-01-19"},{"id":"a49b9b8a-3042-45b6-8ed2-2bec803311ce","acronym":"PLANETTE","url":"https://clinicaltrials.gov/study/NCT04564027","created_at":"2021-01-18T21:48:21.128Z","updated_at":"2024-07-02T16:35:26.185Z","phase":"Phase 2","brief_title":"A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer","source_id_and_acronym":"NCT04564027 - PLANETTE","lead_sponsor":"AstraZeneca","biomarkers":" ATM","pipe":" | ","alterations":" ATM mutation","tags":["ATM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 04/28/2023","primary_completion_date":" 04/28/2023","study_txt":" Completion: 02/05/2024","study_completion_date":" 02/05/2024","last_update_posted":"2023-12-14"},{"id":"54581c85-9056-42be-a8c2-0e2e5d494d11","acronym":"ATRiBRAVE","url":"https://clinicaltrials.gov/study/NCT05582538","created_at":"2022-10-17T13:56:00.812Z","updated_at":"2025-02-25T15:00:40.759Z","phase":"Phase 2","brief_title":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel","source_id_and_acronym":"NCT05582538 - ATRiBRAVE","lead_sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 amplification • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • albumin-bound paclitaxel • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-09-27"},{"id":"a5429dcf-a41d-4257-9cae-ba1a0577a8a5","acronym":"TRAP","url":"https://clinicaltrials.gov/study/NCT03787680","created_at":"2021-06-10T07:53:26.814Z","updated_at":"2024-07-02T16:35:44.793Z","phase":"Phase 2","brief_title":"Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)","source_id_and_acronym":"NCT03787680 - TRAP","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 10/31/2019","start_date":" 10/31/2019","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-06-26"},{"id":"5d48ca1c-897a-41c8-9170-c90e8cff5ce0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03780608","created_at":"2021-01-18T18:41:55.942Z","updated_at":"2024-07-02T16:36:08.720Z","phase":"Phase 2","brief_title":"This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)","source_id_and_acronym":"NCT03780608","lead_sponsor":"Samsung Medical Center","biomarkers":" ATM","pipe":" | ","alterations":" ATM expression","tags":["ATM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-06-15"},{"id":"b4f97d7a-c37d-4460-84f2-c5e208b3f2a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03022409","created_at":"2021-02-22T18:15:48.652Z","updated_at":"2024-07-02T16:36:26.707Z","phase":"Phase 1","brief_title":"A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).","source_id_and_acronym":"NCT03022409","lead_sponsor":"AstraZeneca","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 09/18/2017","start_date":" 09/18/2017","primary_txt":" Primary completion: 01/20/2021","primary_completion_date":" 01/20/2021","study_txt":" Completion: 01/20/2021","study_completion_date":" 01/20/2021","last_update_posted":"2021-08-10"},{"id":"612fbf98-df03-4b92-8660-41c55706f3f1","acronym":"DUETTE","url":"https://clinicaltrials.gov/study/NCT04239014","created_at":"2021-01-18T20:36:32.702Z","updated_at":"2024-07-02T16:36:33.488Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.","source_id_and_acronym":"NCT04239014 - DUETTE","lead_sponsor":"AstraZeneca","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/07/2020","start_date":" 08/07/2020","primary_txt":" Primary completion: 01/25/2021","primary_completion_date":" 01/25/2021","study_txt":" Completion: 01/25/2021","study_completion_date":" 01/25/2021","last_update_posted":"2021-03-10"},{"id":"c3fca746-2c87-4c39-b71e-3fcf60265718","acronym":"PHOENIX","url":"https://clinicaltrials.gov/study/NCT03740893","created_at":"2021-01-18T18:19:29.637Z","updated_at":"2025-02-25T15:08:06.285Z","phase":"Phase 2","brief_title":"PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer","source_id_and_acronym":"NCT03740893 - PHOENIX","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" HER-2 • ER • PGR • BRCA1 • CD8 • IFNG • LAG3 • BIRC5 • CXCL9 • PARP1 • TYMS • PTTG1 • RRM2 • CDC20 • CCNB1 • CEP55 • UBE2C","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • BRCA1 • CD8 • IFNG • LAG3 • BIRC5 • CXCL9 • PARP1 • TYMS • PTTG1 • RRM2 • CDC20 • CCNB1 • CEP55 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 10/15/2019","start_date":" 10/15/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2020-02-21"}]